Recently, a phase II clinical trial of the GP2 peptide-based vaccine, under the vaccine ID NCT00524277, showed groundbreaking outcomes of a 100% 5-year survival rate in patients with HER2+ breast cancer (223). Here, ERBB2 is linked to breast cancer.